PT - JOURNAL ARTICLE AU - Yoshimi, Kazuto AU - Takeshita, Kohei AU - Yamayoshi, Seiya AU - Shibumura, Satomi AU - Yamauchi, Yuko AU - Yamamoto, Masaki AU - Yotsuyanagi, Hiroshi AU - Kawaoka, Yoshihiro AU - Mashimo, Tomoji TI - Rapid and accurate detection of novel coronavirus SARS-CoV-2 using CRISPR-Cas3 AID - 10.1101/2020.06.02.20119875 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.02.20119875 4099 - http://medrxiv.org/content/early/2020/06/02/2020.06.02.20119875.short 4100 - http://medrxiv.org/content/early/2020/06/02/2020.06.02.20119875.full AB - Novel coronavirus SARS-CoV-2 outbreaks have rapidly spread to multiple countries, highlighting the urgent necessity for fast, sensitive, and specific diagnostic tools for virus surveillance. Here, the previously unknown collateral single-stranded DNA cleavage we observed with type I CRISPR-Cas3 highlights its potential for development as a Cas3-mediated rapid (within 40 min), low-cost, instrument-free detection method for SARS-CoV-2. This Cas3-based assay is comparable with Cas12- and real-time reverse-transcriptase PCR-based assays in its speed and sensitivity, but offers greater specificity for single-base-pair discrimination while negating the need for highly trained operators. These findings support the use of CRISPR diagnostics for point-of-care testing in patients with suspected SARS-CoV-2 infections.Competing Interest StatementS.S. is employee of C4U. K.Y. and T.M. are co-founders and scientific advisors for C4U. The other authors declare no competing interests.Funding StatementThis project was supported in part by JSPS KAKENHI Grant Number 18H03974 (T.M.) and 19K16025 (K.Y.). Partially support also came from the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED under Grant Number JP20am0101070 (support numbers 1251 and 2463), from Research Program on Emerging and Re-emerging Infectious Diseases from AMED (JP19fk0108113), and from the National Institutes of Allergy and Infectious Diseases funded Center for Research on Influenza Pathogenesis (CRIP; HHSN272201400008C).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Clinical nasopharyngeal and oropharyngeal swab samples from patients infected with SARS-CoV-2 were collected by IMSUT hospital, according to protocols that were approved by the Research Ethics Review Committee of the Institute of Medical Science, the University of Tokyo.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding authors upon reasonable request.